KNOW YOUR PATIENTS
KNOW THEIR RISK**

** Hereditary risk up to 87% by age 70
Breast

Hereditary risk up to 63% by age 70
Ovarian

Hereditary risk up to 71% by age 70
Endometrial

Hereditary risk up to 20% by age 70
Prostate

Hereditary risk up to 76% by age 80
Melanoma

Hereditary risk up to 36% by age 70
Pancreatic

Hereditary risk up to 99% by age 70
Colon

Hereditary risk up to 80% by age 80
Gastric

General Population Risk: 0.5% by age 70
Pancreatic

General Population Risk: 7.3% by age 70
Breast

General Population Risk: 0.7% by age 70
Ovarian

General Population Risk: 1.6% by age 70
Endometrial

General Population Risk: 8.2% by age 70
Prostate

General Population Risk: 1.6% by age 80
Melanoma
## RED FLAGS FOR HEREDITARY CANCER

An individual with a personal or family history of **any ONE of the following:**

### MULTIPLE CANCERS

A combination of cancers on the same side of the family

- **2 or more:** breast / ovarian / prostate / pancreatic cancer
- **2 or more:** colorectal / endometrial / ovarian / gastric / pancreatic / other cancers (i.e., ureter/renal pelvis, biliary tract, small bowel, brain, sebaceous adenomas)
- **2 or more:** melanoma / pancreatic cancer

### YOUNG CANCERS

Any 1 of the following cancers at age **50 or younger**

- Breast cancer
- Colorectal cancer
- Endometrial cancer

### RARE CANCERS

Any 1 of these rare presentations at **any age**

- Ovarian cancer
- Breast: male breast cancer or triple negative breast cancer
- Colorectal cancer with abnormal MSI/IHC, MSI associated histology
- Endometrial cancer with abnormal MSI/IHC
- 10 or more gastrointestinal polyps

Certain ancestries may have greater risk for hereditary cancer syndromes (e.g., Ashkenazi Jewish ancestry)

---

Assessment criteria based on medical society guidelines. For these individual medical society guidelines, go to www.MyriadPro.com/guidelines.

Family members include first-, second-, and third-degree blood relatives on both your mother’s and father’s sides.

*Adenomatous type. ††Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.

**For the most up-to-date general population, gene-associated cancer risks, management criteria, and other syndrome-related cancers not listed here refer to the Gene Tables located at https://www.MyriadPro.com/myRisk/v

Risks are for patients who have never had cancer. Patients with hereditary risk may have increased risk for other syndrome related cancers.


Myriad, the Myriad logo, Myriad myRisk and the Myriad myRisk logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2016, Myriad Genetic Laboratories, Inc. MRHCRFC/4-16